We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

154 hedge funds and large institutions have $347M invested in PDL BioPharma, Inc. in 2018 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 31 increasing their positions, 63 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

196% more call options, than puts

Call options by funds: $148K | Put options by funds: $50K

20% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 20

5% more capital invested

Capital invested by funds: $329M → $347M (+$17.6M)

1% more funds holding

Funds holding: 152 → 154 (+2)

51% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 63

Holders
154
Holders Change
+2
Holders Change %
+1.32%
% of All Funds
3.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
31
Reduced
63
Closed
20
Calls
$148K
Puts
$50K
Net Calls
+$98K
Net Calls Change
-$178K

Top Buyers

Rank Fund Capital Flow
1
BIP
Brandes Investment Partners
California
+$1.45M
2
Prudential Financial
Prudential Financial
New Jersey
+$1.28M
3
RC
RBF Capital
California
+$1.15M
4
UBS Group
UBS Group
Switzerland
+$891K
5
Citigroup
Citigroup
New York
+$857K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$4.73M
2
State Street
State Street
Massachusetts
-$2.93M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.44M
4
Deutsche Bank
Deutsche Bank
Germany
-$2.14M
5
AQR Capital Management
AQR Capital Management
Connecticut
-$1.74M

PDLI Hedge Fund Activity: Q4 2018 in Review

154 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q4 2018, worth a combined $347M — up 5.3% from $329M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new PDLI positions and 20 closed out — a net gain of 4 holders — while 31 added to existing stakes and 63 trimmed.

The largest buyer was Brandes Investment Partners, adding an estimated $1.45M. The largest seller was Armistice Capital, exiting entirely with an estimated $4.73M sold.

  • 154 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q4 2018, up from 152 in Q3 2018.
  • Funds reported $347M of PDL BioPharma, Inc. stock for Q4 2018, up 5.3% quarter-over-quarter.
  • 24 funds opened new PDL BioPharma, Inc. positions in Q4 2018 and 20 closed out, a net change of +4 holders.
  • The largest PDL BioPharma, Inc. buyer in Q4 2018 was Brandes Investment Partners, an estimated $1.45M added.
  • The largest PDL BioPharma, Inc. seller in Q4 2018 was Armistice Capital, an estimated $4.73M sold.

Based on aggregated 13F filings for Q4 2018.